Skip to main content
Clinical Trials/NL-OMON50243
NL-OMON50243
Completed
Not Applicable

Clinical Evaluation of the StablePoint Catheter and Force-Sensing System for Paroxysmal Atrial Fibrillation - NEWTON AF

Boston Scientific0 sites20 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation - Abnormal heart rhythm
Sponsor
Boston Scientific
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • \* History of recurrent symptomatic Paroxysmal Atrial Fibrillation (PAF),
  • defined as atrial fibrillation (AF) that terminates spontaneously or with
  • intervention (either procedure or drug therapy) within seven days of onset.
  • Minimum documentation includes the following:
  • o a physician\*s note indicating recurrent self\-terminating atrial fibrillation
  • (AF) which includes at least two symptomatic AF episodes in the patient\*s
  • history within the last 6 months prior to enrollment, and
  • o any electrocardiographically documented AF episode within 12 months prior to
  • enrollment.
  • \* Subjects who are eligible for an ablation procedure for PAF according to 2017

Exclusion Criteria

  • \* Subjects with New York Heart Association (NYHA) Class III or IV heart failure
  • \< 180 days prior to enrollment
  • \* Left atrial diameter \> 5\.0 cm or left atrial volume \>50 ml/m² indexed based
  • on the most recent echocardiography
  • \* Left ventricular ejection fraction \< 35% based on the most recent
  • echocardiogram
  • \* Continuous AF lasting longer than seven (7\) days
  • \* Subjects who have undergone any previous left atrial cardiac ablation (RF,
  • Cryo, surgical)
  • \* Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or

Outcomes

Primary Outcomes

Not specified

Similar Trials